Biomarkers of Alzheimer disease, insulin resistance, and obesity in childhood

Pediatrics

Volumn 135, Issue 6, 2015, Pages 1074-1081

  Luciano, Rosa ^a   Barraco, Gloria Maria ^a   Muraca, Maurizio ^a   Ottino, Simonetta ^a   Spreghini, Maria Rita ^a   Sforza, Rita Wietrzykowska ^a   Rustico, Carmela ^a   Morino, Giuseppe Stefano ^a   Manco, Melania ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; PRESENILIN 1; TRIACYLGLYCEROL; URIC ACID; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); BIOLOGICAL MARKER; PEPTIDE FRAGMENT;

ADOLESCENT; ALZHEIMER DISEASE; ARTICLE; BODY MASS; CHILD; CHILDHOOD OBESITY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HIGH RISK POPULATION; HOMEOSTASIS MODEL OF INSULIN RESISTANCE; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; MOLECULAR PATHOLOGY; NEUROPATHOLOGY; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; QUANTITATIVE INSULIN SENSITIVITY CHECK INDEX; RISK ASSESSMENT; SCHOOL CHILD; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL; WESTERN BLOTTING; BLOOD; CROSS-SECTIONAL STUDY; OBESITY;

ADOLESCENT; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; BIOMARKERS; BODY MASS INDEX; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; OBESITY; PEPTIDE FRAGMENTS; PRESENILIN-1;

EID: 84930580472     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2014-2391     Document Type: Article

References (59)

1. Chen Z, Zhong C. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. Prog Neurobiol. 2013;108:21-43
2. De Felice FG, Lourenco MV, Ferreira ST. How does brain insulin resistance develop in Alzheimer's disease? Alzheimers Dement. 2014;10(suppl 1):S26-S32
3. Sebastião I, Candeias E, Santos MS, de Oliveira CR, Moreira PI, Duarte AI. Insulin as a bridge between type 2 diabetes and Alzheimer disease: how anti-diabetics could be a solution for dementia. Front Endocrinol (Lausanne). 2014;5:110
4. Kroner Z. The relationship between Alzheimer's disease and diabetes: type 3 diabetes? Altern Med Rev. 2009;14(4):373-379
5. Pasquier F, Boulogne A, Leys D, Fontaine P. Diabetes mellitus and dementia. Diabetes Metab. 2006;32(5 pt 1):403-414
6. Gorospe EC, Dave JK. The risk of dementia with increased body mass index. Age Ageing. 2007;36(1):23-29
7. Jayaraman A, Pike CJ. Alzheimer's disease and type 2 diabetes: multiple mechanisms contribute to interactions. Curr Diab Rep. 2014;14(4):476
8. Luchsinger JA, Tang MX, Shea S, Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology. 2004;63(7):1187-1192
9. Profenno LA, Porsteinsson AP, Faraone SV. Meta-analysis of Alzheimer's disease risk with obesity, diabetes, and related disorders. Biol Psychiatry. 2010;67(6):505-512
10. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol. 2004;61(5):661-666
11. Rawlings AM, Sharrett AR, Schneider AL, et al. Diabetes in midlife and cognitive change over 20 years: a cohort study. Ann Intern Med. 2014;161(11):785-793
12. Tuligenga RH, Dugravot A, Tabák AG, et al. Midlife type 2 diabetes and poor glycaemic control as risk factors for cognitive decline in early old age: a post-hoc analysis of the Whitehall II cohort study. Lancet Diabetes Endocrinol. 2014;2(3):228-235
13. Cukierman T, Gerstein HC, Williamson JD. Cognitive decline and dementia in diabetes - systematic overview of prospective observational studies. Diabetologia. 2005;48(12):2460-2469
14. Biessels GJ, Kappelle LJ; Utrecht Diabetic Encephalopathy Study Group. Increased risk of Alzheimer's disease in Type II diabetes: insulin resistance of the brain or insulin-induced amyloid pathology? Biochem Soc Trans. 2005;33(pt 5):1041-1044
15. Tabaton M, Zhu X, Perry G, Smith MA, Giliberto L. Signaling effect of amyloid-beta(42) on the processing of AbetaPP. Exp Neurol. 2010;221(1):18-25
16. Goate A, Chartier-Harlin MC, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 1991;349(6311):704-706
17. De Strooper B. Loss-of-function presenilin mutations in Alzheimer disease. Talking Point on the role of presenilin mutations in Alzheimer disease. EMBO Rep. 2007;8(2):141-146
18. Steiner H, Fluhrer R, Haass C. Intramembrane proteolysis by gamma-secretase. J Biol Chem. 2008;283(44):29627-29631
19. Ohki Y, Shimada N, Tominaga A, et al. Binding of longer Aβ to transmembrane domain 1 of presenilin 1 impacts on Aβ42 generation. Mol Neurodegener. 2014;9:7
20. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007;8(2):101-112
21. Yang Y, Song W. Molecular links between Alzheimer's disease and diabetes mellitus. Neuroscience. 2013;250:140-150
22. Schupf N, Patel B, Pang D, et al. Elevated plasma beta-amyloid peptide Abeta(42) levels, incident dementia, and mortality in Down syndrome. Arch Neurol. 2007;64(7):1007-1013
23. Ida N, Hartmann T, Pantel J, et al. Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J Biol Chem. 1996;271(37):22908-22914
24. Mayeux R, Honig LS, Tang MX, et al. Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology. 2003;61(9):1185-1190
25. Reitz C. Alzheimer's disease and the amyloid cascade hypothesis: a critical review. Int J Alzheimers Dis. 2012;2012:369808.
26. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA. 2014;311(8):806-814
27. Yau PL, Castro MG, Tagani A, Tsui WH, Convit A. Obesity and metabolic syndrome and functional and structural brain impairments in adolescence. Pediatrics. 2012;130(4). Available at: www.pediatrics.org/cgi/content/full/130/4/e856
28. Shashaj B, Bedogni G, Graziani MP, et al. Origin of cardiovascular risk in overweight preschool children: a cohort study of cardiometabolic risk factors at the onset of obesity. JAMA Pediatr. 2014;168(10):917-924
29. Mizock BA. Alterations in carbohydrate metabolism during stress: a review of the literature. Am J Med. 1995;98(1):75-84
30. Cole TJ, Bellizzi MC, Flegal KM, Dietz WH. Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ. 2000;320(7244):1240-1243
31. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-419
32. Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85(7):2402-2410
33. Oh YS, Turner RJ. Protease digestion indicates that endogenous presenilin 1 is present in at least two physical forms. Biochem Biophys Res Commun. 2006;346(1):330-334
34. Balakrishnan K, Verdile G, Mehta PD, et al. Plasma Abeta42 correlates positively with increased body fat in healthy individuals. J Alzheimers Dis. 2005;8(3):269-282
35. Mayeux R, Schupf N. Blood-based biomarkers for Alzheimer's disease: plasma Ab40 and Ab42, and genetic variants. Neurobiol Aging. 2011;32(suppl 1):S10-S19
36. Schupf N, Tang MX, Fukuyama H, et al. Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease. Proc Natl Acad Sci U S A. 2008;105(37):14052-14057
37. van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MMB. Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol. 2006;5(8):655-660
38. Gabelle A, Richard F, Gutierrez LA, et al. Plasma amyloid-b levels and prognosis in incident dementia cases of the 3-City Study. J Alzheimers Dis. 2013;33(2):381-391
39. Lee Y-H, Martin JM, Maple RL, Tharp WG, Pratley RE. Plasma amyloid-beta peptide levels correlate with adipocyte amyloid precursor protein gene expression in obese individuals. Neuroendocrinology. 2009;90(4):383-390
40. de la Monte SM. Insulin resistance and Alzheimer's disease. BMB Rep. 2009;42(8):475-481
41. Umegaki H. Pathophysiology of cognitive dysfunction in older people with type 2 diabetes: vascular changes or neurodegeneration? Age Ageing. 2010;39(1):8-10
42. Craft S. Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. Curr Alzheimer Res. 2007;4(2):147-152
43. Odetti P, Piccini A, Giliberto L, et al. Plasma levels of insulin and amyloid beta 42 are correlated in patients with amnestic mild cognitive impairment. J Alzheimers Dis. 2005;8(3):243-245
44. Hotamisligil GS. Molecular mechanisms of insulin resistance and the role of the adipocyte. Int J Obes Relat Metab Disord. 2000;24(suppl 4):S23-27
45. Nguyen JC, Killcross AS, Jenkins TA. Obesity and cognitive decline: role of inflammation and vascular changes. Front Neurosci. 2014;8:375
46. Gemma C, Bickford PC. Interleukin-1beta and caspase-1: players in the regulation of age-related cognitive dysfunction. Rev Neurosci. 2007;18(2):137-148
47. Jankowsky JL, Patterson PH. Cytokine and growth factor involvement in long-term potentiation. Mol Cell Neurosci. 1999;14(6):273-286
48. Trollor JN, Smith E, Agars E, et al. The association between systemic inflammation and cognitive performance in the elderly: the Sydney Memory and Ageing Study. Age (Dordr). 2012;34(5):1295-1308
49. Koyama A, O'Brien J, Weuve J, Blacker D, Metti AL, Yaffe K. The role of peripheral inflammatory markers in dementia and Alzheimer's disease: a meta-analysis. J Gerontol A Biol Sci Med Sci. 2013;68(4):433-440
50. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9(1):46-56
51. Kakuda N, Shoji M, Arai H, et al; Japanese Alzheimer's Disease Neuroimaging Initiative. Altered γ-secretase activity in mild cognitive impairment and Alzheimer's disease. EMBO Mol Med. 2012;4(4):344-352
52. Borghi R, Piccini A, Barini E, et al. Upregulation of presenilin 1 in brains of sporadic, late-onset Alzheimer's disease. J Alzheimers Dis. 2010;22(3):771-775
53. Mathews PM, Cataldo AM, Kao BH, et al. Brain expression of presenilins in sporadic and early-onset, familial Alzheimer's disease. Mol Med. 2000;6(10):878-891
54. Verdile G, Gnjec A, Miklossy J, et al. Protein markers for Alzheimer disease in the frontal cortex and cerebellum. Neurology. 2004;63(8):1385-1392
55. Maesako M, Uemura K, Kuzuya A, et al. Gain of function by phosphorylation in Presenilin 1-mediated regulation of insulin signaling. J Neurochem. 2012;121(6):964-973
56. Ascaso JF, Pardo S, Real JT, Lorente RI, Priego A, Carmena R. Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care. 2003;26(12):3320-3325
57. d'Annunzio G, Vanelli M, Pistorio A, et al; Diabetes Study Group of the Italian Society for Pediatric Endocrinology and Diabetes. Insulin resistance and secretion indexes in healthy Italian children and adolescents: a multicentre study. Acta Biomed. 2009;80(1):21-28
58. Barnea-Goraly N, Raman M, Mazaika P, et al; Diabetes Research in Children Network (DirecNet). Alterations in white matter structure in young children with type 1 diabetes. Diabetes Care. 2014;37(2):332-340
59. Kail RV, Cavanaugh JC. Human Development: A Life-Span View. 5th ed. Belmont, CA: Wadsworth; 2010